Details for Patent: 11,097,063
✉ Email this page to a colleague
Which drugs does patent 11,097,063 protect, and when does it expire?
Patent 11,097,063 protects OZEMPIC and is included in one NDA.
This patent has fifteen patent family members in thirteen countries.
Summary for Patent: 11,097,063
| Title: | Syringe device with a dose limiting mechanism and an additional safety mechanism |
| Abstract: | A syringe device for ejecting a dose of a medicament, the syringe device comprising: a dose limiting mechanism arranged to interact with a dose ejecting mechanism to prevent ejection of a dose exceeding a set dose, and a safety mechanism, which is arranged such with respect to the dose ejecting mechanism that, if the dose limiting mechanism fails, the safety mechanism prevents ejection of a dose exceeding the set dose. |
| Inventor(s): | Jacob Eiland, Christian Peter Enggaard, Claus Schmidt Moeller, Tom Hede Markussen |
| Assignee: | Novo Nordisk AS |
| Application Number: | US16/250,620 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,097,063 |
|
Patent Claim Types: see list of patent claims | Use; Device; |
Drugs Protected by US Patent 11,097,063
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-001 | Dec 5, 2017 | DISCN | Yes | No | 11,097,063 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-004 | Oct 6, 2022 | RX | Yes | Yes | 11,097,063 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-002 | Apr 9, 2019 | RX | Yes | Yes | 11,097,063 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-003 | Mar 28, 2022 | RX | Yes | Yes | 11,097,063 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 11,097,063
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 05016286 | Jul 27, 2005 | |
International Family Members for US Patent 11,097,063
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | E447992 | ⤷ Start Trial | |||
| Australia | 2006278928 | ⤷ Start Trial | |||
| Brazil | PI0613926 | ⤷ Start Trial | |||
| Canada | 2616248 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
